Compare FFIC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | VNDA |
|---|---|---|
| Founded | 1929 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.1M | 474.0M |
| IPO Year | 1996 | 2005 |
| Metric | FFIC | VNDA |
|---|---|---|
| Price | $14.96 | $8.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $16.80 | $14.90 |
| AVG Volume (30 Days) | 175.2K | ★ 3.4M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | ★ 151.43 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | $7,455,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $14.57 | $21.50 |
| Revenue Next Year | $6.64 | $38.67 |
| P/E Ratio | $27.74 | ★ N/A |
| Revenue Growth | 7.31 | ★ 8.72 |
| 52 Week Low | $10.65 | $3.81 |
| 52 Week High | $17.79 | $9.91 |
| Indicator | FFIC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 54.51 |
| Support Level | $14.44 | $7.39 |
| Resistance Level | $15.57 | $9.53 |
| Average True Range (ATR) | 0.40 | 0.54 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 6.36 | 41.58 |
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.